tbuckley/cabot-search huggingface dataset:
Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years
Authors: J-Y Cahn, M Labopin, A Schattenberg, J Reiffers, R Willemze, R Zittoun, A Bacigalupo, G Prentice, E Gluckman, P Hervé, A Gratwohl, N-C Gorin
Journal: Leukemia (1997)
Bigger data for big data: From Twitter to brain–computer interfaces
Authors: Etienne B. Roesch, Frederic Stahl, Mohamed Medhat Gaber
Journal: Behavioral and Brain Sciences (2014)

Abstract We are sympathetic with Bentley et al.’s attempt to encompass the wisdom of crowds in a generative model, but posit that a successful attempt at using big data will include more sensitive measurements, more varied sources of information, and will also build from the indirect information available through technology, from ancillary technical features to data from brain–computer interfaces.
Peroxisome Proliferator-Activated Receptor δ Regulates Extracellular Matrix and Apoptosis of Vascular Smooth Muscle Cells Through the Activation of Transforming Growth Factor-β1/Smad3
Authors: Hyo Jung Kim, Min Young Kim, Hana Jin, Hyun Joon Kim, Sang Soo Kang, Hye Jung Kim, Jae Heun Lee, Ki Churl Chang, Jin-Yong Hwang, Chihiro Yabe-Nishimura, Jin-Hoi Kim, Han Geuk Seo
Journal: Circulation Research (2009)

Homeostasis of the extracellular matrix and apoptosis of vascular smooth muscle cells (VSMCs) are key components in the regulation of the stability of atherosclerotic plaques. Here, we demonstrate that peroxisome proliferator-activated receptor (PPAR)δ regulates extracellular matrix synthesis and degradation through transforming growth factor-β1 and its effector, Smad3. Activation of PPARδ strongly amplified the expression of types I and III collagen, fibronectin, elastin, and TIMP-3 (tissue inhibitor of metalloproteinases 3), but not of TIMP-1, matrix metalloproteinase-2 or -9. The effect of PPARδ on the expression of type III collagen was dually regulated by the direct binding of PPARδ and Smad3 to a direct repeat-1 site and a Smad-binding element, respectively, in the type III collagen gene promoter. The activation of PPARδ attenuated apoptotic cell death in VSMCs induced by oxidized low-density lipoprotein, and similar antiapoptotic effects were observed on treatment of cells with exogenous type I and/or III collagen. Administration of a PPARδ ligand GW501516 to mice also suppressed elastase-induced cell death of aortic VSMCs. These results suggest that PPARδ-induced upregulation of extracellular matrix proteins exerts an antiapoptotic effect, thereby maintaining the stability of atherosclerotic plaques. Specific ligands of PPARδ may aid in the therapeutic intervention of atherosclerosis by improving plaque stability and patient prognosis.
Two doctors are banned from acting as company directors after failing to pass on pension contributions
Authors: N. Hawkes
Journal: BMJ (2012)

Two North London GPs and another man who ran Camidoc, an out of hours service provider, have been banned from acting as company directors for periods totalling more than 14 years after failing to pass on over £700 000 (€870 000; $1.1m) of NHS pension contributions.

The three men—Michael Golding of East Barnet and the GPs Mayor Gor of Finchley and Ivor Robinson of Highgate—were using the money to keep the company afloat after it ran into financial difficulties in the period …
The Surgeon's Handbook
Authors: Robert E. Hermann
Journal: JAMA (1982)

This soft-cover handbook is designed for the beginning medical student or surgical resident, to be used as a concise reference book, which can be carried in the pocket. In the preface, the author states that this book was designed as "a concise textbook covering the entire field of surgery... a condensed presentation like a skeleton of the entire body." The book is 552 pages in length and is divided into two sections. Part 1 covers general topics and the management of various presenting complaints including the history and physical examination, organization of the medical record, neck masses, breast examination, dysphagia, abdominal pain, gastrointestinal bleeding, jaundice, change in bowel habits, lung mass, and hemoptysis. Part 2 is an organized review of various surgical problems or diseases including preoperative evaluation and preparation of the patient for an operative procedure, preoperative and postoperative orders, postoperative complications, fluids and electrolytes, infection, shock, nutrition, and
Abstract 843: Influx of thiosemicarbazone NSC73306 is mediated by the cisplatin and copper transporter SLC31A1 (CTR1)
Authors: King Leung Fung, Abisola K. Tepede, Kristen M. Pluchino, Matthew D. Hall, Michael M. Gottesman
Journal: Cancer Research (2012)

Abstract Multidrug resistance (MDR) mediated via the drug efflux pump P-glycoprotein (P-gp/ABCB1) overexpression is a major obstacle to the success of chemotherapy to combat many cancers. Clinically, P-gp expression correlates with poor clinical response to chemotherapy in patients, and its presence on the blood-brain barrier (BBB) can reduce the efficacy of otherwise promising agents targeted to the brain. Attempts to reverse drug resistance by inhibiting P-gp have not been successful, and we have been investigating alternative strategies for targeting multidrug-resistant (MDR) cancer cells. One such strategy is the use of NSC73306, a thiosemicarbazone compound that is selectively toxic towards P-gp-expressing cells. Here, we investigate the cellular uptake of NSC73306, and examine its interaction with P-gp and copper transporter 1 (SLC31A1, CTR1). In porcine kidney epithelial LLC-PK1 cells, cellular accumulation of NSC73306 is saturable, and overexpression of human P-gp in LLC-PK1 cells sensitizes them to NSC73306. Accumulation of [3H]NSC73306 in LLC-PK1 cells is inhibited by cyclosporin A (IC50 = 500 μM), verapamil (IC50= 700 μM) and cisplatin (IC50 = 77 μM). Among these compounds, we tested the effect of cisplatin on NSC73306. Selective toxicity of NSC73306 to P-gp-expressing LLC-PK1 cells was reversed by cisplatin in a dose-dependent manner (up to 40 μM). In contrast, the amount of cisplatin required to kill 50% of LLC-PK1 cells was not affected by increasing the amount of NSC73306 (up to 2μM). Since cisplatin could inhibit NSC73306 uptake, we hypothesize that these two compounds share a common uptake pathway, but cisplatin has additional routes of entry into cells. Cells transiently expressing CTR1 showed significantly higher [3H]NSC73306 accumulation. In contrast, CTR1 knockdown cells had lower [3H]NSC73306 uptake. Although cisplatin is a transport substrate of CTR1, we found that CTR1 protein was overexpressed in cisplatin-resistant KB-CP20 and BEL7404-CP20 cell lines. Compared to their parental cisplatin-sensitive cells, even though these resistance cells show decreased cisplatin accumulation, suggesting that CTR1 is not rate-limited for cisplatin uptake. These cell lines also showed higher [3H]NSC73306 uptake compared to their parental cells. In contrast, MDR cell lines overexpressing P-gp had unchanged CTR1 protein levels. Incubation with NSC73306 for 24 hours down-regulated CTR1 in a dose-dependent manner. These results suggest that NSC73306 is a transport substrate of CTR1. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 843. doi:1538-7445.AM2012-843
The zebrafish spi1 promoter drives myeloid-specific expression in stable transgenic fish
Authors: Alister C. Ward, Dora O. McPhee, Melanie M. Condron, Sony Varma, Stephen H. Cody, Sara M. N. Onnebo, Barry H. Paw, Leonard I. Zon, Graham J. Lieschke
Journal: Blood (2003)
NAMPT is essential for the G-CSF–induced myeloid differentiation via a NAD+–sirtuin-1–dependent pathway
Authors: Julia Skokowa, Dan Lan, Basant Kumar Thakur, Fei Wang, Kshama Gupta, Gunnar Cario, Annette Müller Brechlin, Axel Schambach, Lars Hinrichsen, Gustav Meyer, Matthias Gaestel, Martin Stanulla, Qiang Tong, Karl Welte
Journal: Nature Medicine (2009)
Tree‐pollen allergy is efficiently treated by short‐term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens
Authors: B. R. Balda, H. Wolf, C. Baumgarten, L. Klimek, G. Rasp, G. Kunkel, S. Müller, W. Mann, B. Hauswald, W. Heppt, B. Przybilla, U. Amon, R. Bischoff, G. Becher, S. Hummel, P. J. Frosch, T. Rustemeyer, L. Jäger, R. Brehler, J. Schnitker
Journal: Allergy (1998)

The efficacy and tolerance of short‐term immunotherapy (STI) by seven preseasonal injections of tree‐pollen allergens (ALK7 FrUhbltihermischung®) was investigated in a double‐blind, placebo‐controlled, multicenter study with 111 rhinoconjunctivitis patients. Nasal and bronchial symptoms simultaneously analyzed, and nasal symptoms as a single end point, but not the overall score of nasal, bronchial, and conjunctival symptoms, showed a significantly lower increase with STI during birch‐pollen exposure (both P = 0.033, n = 105, Mann‐Whitney U‐test). However, a selective analysis with patients from centers with high recruitment figures ( n S10 patients, n =29 STI, n =32 placebo) showed a significantly lower increase of nasal, bronchial, and overall symptom score (STI 11.0 vs placebo 18.0, P=0.001, U‐test). STI had equidirected effects on conjunctival, nasal, and bronchial symptoms analyzed as multiple end points, although conjunctival symptoms were not significantly different as a single end point. The seasonal increase in drug use was reduced by 62% in the STI group compared with placebo (P=0.032, Mest), Specific IgG4 increased only after STI (P&lt;0,001); IgE was not significantly different. Eosinophil cationic protein remained unchanged with STI, but significantly increased with placebo in the pollen season (P=Qm3). STI was well tolerated. In conclusion, STI was shown to be efficacious and safe for the treatment of patients with tree‐pollen rhinoconjunctivitis.
Trends of Antibiotic Use In the United States
Authors: Hobart A. Reimann
Journal: JAMA (1974)

To the Editor.—  Divergent views appear in the series of comments on antimicrobic usage (227:1023-1032 and 1048-1049, 1974). Ballin et al are skeptical of Simmons and Stolley's critique despite the supportive data in their cited references, and in Kunin's, Howell's, and the editor's comments, whose conclusions and recommendations are hardly preliminary. The references to Finland and Weinstein that are cited by Simmons and Stolley, and other opinions, cannot be discredited, and Cluff's contributions are not mentioned. Similar critique of overuse, misuse, and ensuing harmful results appeared regularly for years in issues of theMedical Letterand in annual reviews of infectious diseases in theArchives of Internal Medicine, thePostgraduate Medical Journal, and elsewhere (Med Clin N Am45:849, 1961;Arch Environ Health13:631, 1966;JAMA205:537, 1968). Granted that accurate data are diffcult to collect, how much more definitive or hard facts are needed to portray the overuse of
Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line
Authors: Taikoh Dohjima, Nan Sook Lee, Haitang Li, Takatoshi Ohno, John J Rossi
Journal: Molecular Therapy (2003)

The EWS/Fli-1 fusion gene encodes an oncogenic fusion protein. The fusion is a product of the translocation t(11;22) (q24;q12), which is detected in 85% of Ewing sarcoma and primitive neuroectodermal tumor cells. Utilizing intracellularly expressed 21- to 23-nucleotide small interfering RNAs (siRNAs) targeting the EWS/Fli-1 fusion transcript in an Ewing sarcoma cell line, we achieved a greater than 80% reduction in the EWS/Fli-1 transcript. The reduction in transcript levels was accompanied by growth inhibition of an Ewing cell line. In addition to quantitating the reduction of the fusion transcript, we carefully monitored reduction of the endogenous EWS and Fli-1 mRNAs as well. One of the two siRNAs targeted to the fusion transcript also partially downregulated the Fli-1 mRNA, further potentiating the growth inhibition. These results highlight both the power of siRNAs and the potential side reactions that need to be carefully monitored. In addition, these results provide the first demonstration of expressed siRNAs downregulating an oncogenic fusion transcript. The results and observations from these studies should prove useful in targeting other fusion transcripts characteristic of sarcomas and erythroleukemias.
Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning
Authors: D HAUSENLOY
Journal: Cardiovascular Research (2004)

Recruitment of the survival kinase cascades, PI3K-Akt and Raf-MEK1/2-Erk1/2, at the time of reperfusion, following a lethal ischemic insult, may mediate the protection associated with ischemic preconditioning (IPC). The exact interplay between these two kinase cascades in mediating this effect is not clear. We examine the 'cross-talk' between these kinase cascades in their contribution to IPC-induced protection.In isolated perfused rat hearts subjected to 35 min of lethal ischemia +/- ischemic preconditioning, the phosphorylation states of Akt, Erk1/2, p70S6K were determined after 15 min of reperfusion, and infarct size was measured after 120 min of reperfusion. IPC induced a threefold increase in Akt, Erk1/2, and p70S6K phosphorylation, at reperfusion. We found that inhibiting the PI3K-Akt (using LY294008) at reperfusion induced the phosphorylation of Erk1/2-p70S6K, and conversely, that inhibiting the MEK1/2-Erk1/2 pathway (using PD 98059) at reperfusion, induced the phosphorylation of Akt, suggesting 'cross-talk' between the two kinase pathways. However, this effect was not accompanied by a reduction in infarct size (43.1 +/- 7.2% with LY 294008 and 57.7 +/- 7.0% with PD 98059 vs. 46.3 +/- 5.8% in control; P = NS), suggesting that both the kinase cascades may need to be activated to mediate IPC-induced protection. IPC reduced the infarct-risk volume ratio to 17.8 +/- 2.3% from 46.3 +/- 5.8% in control (P < 0.01). Inhibiting p70S6K, a kinase situated downstream of both PI3K and Erk1/2, using rapamycin, abolished IPC-induced protection (46.0 +/- 7.7% with IPC+RAPA vs. 17.8 +/- 2.3% with IPC; P < 0.01).We report that, the survival kinase cascades PI3K-Akt and MEK1/2-Erk1/2, which are recruited at the time of reperfusion in response to ischemic preconditioning, exhibit 'cross-talk' such that inhibiting one cascade activates the other and vice versa. Furthermore, at the time of reperfusion, these kinase cascades mediate IPC-induced protection, by acting in concert via p70S6K.
RADIUM'S CONTRIBUTION TO SURGERY
Authors: ROBERT ABBE
Journal: JAMA (1910)

I have long felt that the study of so novel and extraordinary an agent as radium should not be left exclusively to the student of physics or to the dermatologist, but that it be given a chance to demonstrate the virtues residing in it, if any there be, in the field of general surgery. During the seven years past, in which it has been possible to obtain the material, I have taken many occasions to give trial to it, and while knowing my endeavors to demonstrate its utility are far from complete, this much can be said, that without prejudice I have applied it in 500 cases of disease, from the large field of exclusive surgical work and have found enough of interest in its application to warrant my speaking of it in the brief time allotted to me here. From the first I have entertained the attitude of extreme
Admission of old people to psychiatric units
Authors: M Segal, M A Hill
Journal: BMJ (1980)

Listening and talking to patients SIR,-I was delighted to read the first of the articles (27 September, p 845) by Professor Charles Fletcher on the issue of listening and talking to patients.Medical students learn their medicine by following the example of their seniors.While every attention is paid to the acquisition of the facts about the physical condition, too often insufficient attention is paid to associated emotional problems.
Non-smoking wives of heavy smokers have a higher risk of lung cancer
Authors: E. J Macdonald
Journal: BMJ (1981)

Non-smoking wives of heavy smokers have a higher risk of lung cancer H R Kornegay and M A Kastenbaum, phd; N Mantel; J E Harris, md, and W H DuMouchel, phd; Eleanor J Macdonald, md; T Hirayama, md. 914 Statistics in question M F Grayson, mrcp. 917 Caution on preventing neural tube defects V C Talwalkar, md. 917 The right to live and the right to die R B Zachary, frcs. 918 Microcomputers in antenatal care J R Davies, ffarcs. 918 Diving is dangerous for diabetics J D King, MB. 918 Dealing with epileptics Rachel Tavriger. 918 Management of asthma in the child aged under 6 years I Blumenthal, mrcp. 918 Minor orthopaedic problems in children A N Conner, frcsed, and J E Robb, frcsed 919 Reversible renal damage due to glue sniffing Mary D King, MB. 919 Audit in renal failure H J Goldsmith, frcp, and others. 919 Vitamin A toxicity and hypercalcaemia in chronic renal failure M O'Fearghail, MB, and others. 919 Treatment of acute mountain sickness P McDonald, frcs. 919 Proposals for a trial marriage between primary and secondary health care in one or two districts in inner London C J Dickinson, frcp. 920 Junior posts and expansion of the consultant grade A W Banks, frcog. 920 Changes in the MRCP examination M Ross, mrcp, and D M F Gibb, mrcp. .. 920 Will doctors miss out again? R C L Feneley, frcs. 920 Doctors' contracts: an urgent case for legislation J L Taylor, mrcgp ; F E Weale, frcs . Consultant contracts B A Kamdar, frcsed. New technique of drug promotion? J Iqbal, mrcgp. Corrections: Hypokalaemia due to sal butamol overdosage (Corea et al)', Deal? ing with epileptics (Beran and Sutton). .. 921 921
Abstract 2457: Functional Study of DCC Gene in multiple myeloma mell lines
Authors: Dorival Mendes Rodrigues-Junior, Thais Priscilla Biassi, Viviane Carlin, Joel Machado-Junior, André Luiz Vettore
Journal: Cancer Research (2014)

Abstract Functional Study of DCC Gene in Multiple Myeloma Cell Lines ABSTRACT INTRODUCTION: Multiple Myeloma (MM) is an incurable hematological malignancy characterized by multiorgan dysfunction as a result of bone marrow infiltration by malignant cells and the systemic damage of monoclonal circulating protein. Despite considerable progress in understanding MM biology, the molecular basis of this disease still remains open to debate. Previous data showed that DCC gene hypermethylation is significantly correlated with poor prognosis of MM patients. However, the involvement of DCC in the tumorigenesis process of MM remains unclear. PURPOSE: To better understand the role of DCC in this pathology through gene silencing in MM cell lines and evaluation of its interference in different tumorigenic processes. METHODS: The DCC gene expression was evaluated in three MM cell lines (RPMI-8226 and U266) and promoter methylation profile of this gene in the three cell lines was determined. The presence of DCC protein was confirmed by Western blotting (WB). The DCC expression was silenced by esiRNA and transfections were performed by electroporation. RESULTS: We detected the presence of aberrant methylation in DCC promoter in RPMI-8226, a cell line with undetectable expression of DCC. On the other hand, DCC was not methylated in U266, which present expression of DCC at mRNA and protein level. For this reason, DCC was silenced in U266 with esiRNA and its impact in the apoptosis, cell viability, proliferation and cell cycle processes was evaluated in this cell line. Support by FAPESP Citation Format: Dorival Mendes Rodrigues-Junior, Thais Priscilla Biassi, Viviane Carlin, Joel Machado-Junior, André Luiz Vettore. Functional Study of DCC Gene in multiple myeloma mell lines. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2457. doi:10.1158/1538-7445.AM2014-2457
Ciclesonide, administered once daily, has a low incidence of oropharyngeal adverse events in pediatric asthma patients
Authors: E. Gelfand, M. Boguniewicz, S. Weinstein, C. Bernstein, M. Lloyd, P. Zhang, J. Williams, D. Banerji, P. Hamedani
Journal: Journal of Allergy and Clinical Immunology (2005)
ANTIBIOTICS IN TREATMENT OF PANCREATIC FIBROSIS, WITH EMPHASIS ON TERRAMYCIN
Authors: H. Shwachman
Journal: JAMA (1952)

The beneficial effects of aureomycin in the management of patients with pancreatic fibrosis (mucoviscidosis) have been demonstrated.1An extension of observations begun three years ago, and including over 100 patients, shows a favorable response in over 90%. Anticipation of the appearance of refractoriness to aureomycin and the poor response of the occasional patient to aureomycin suggested the use of terramycin.2The present report is an evaluation of terramycin in the treatment of 49 patients with pancreatic fibrosis. All patients, with two exceptions (the patients in cases 2 and 3), had pulmonary infections of varying severity. A brief note concerning the efficacy of terramycin has been made.3A full description of this disease is given elsewhere.4The main clinical features drawing attention to this condition in early infancy are hunger, with failure to gain weight on an adequate caloric intake; the passage of large, foul, and frequent
The Practice of Medicine Act in Congress.
Authors: Samuel C. Busey
Journal: JAMA (1895)

DR. S. C. BUSEY TO THE COMMISSIONERS.  Washington, D. C., February, 1895.   Honorable Commissioners of the District of Columbia .  Gentlemen:  —I am instructed by the Committee on Legislation of the Medical Society of the District of Columbia, to communicate to your Honorable Board the objections of said committee to several provisions of the bill, known as the Commissioners' Bill, and entitled, A bill to regulate the practice of medicine and surgery, to license physicians and surgeons, and to punish persons violating the provisions thereof in the District of Columbia.  The committee of the Medical Society suggests that Sec. 1 be so amended that not more than two of the Board of Medical Supervisors shall be appointed from either of the three systems of medicine recognized in the bill, so that it will be impossible for either of these systems of medicine to acquire a majority of said Board of Medical
Prescribing in Europe--forces for change.
Authors: D. Taylor
Journal: BMJ (1992)

by which we administer care, offers a plausible 2 Schieber GJ, Potullier Jl'.International health spending: isstues and trends.mechanism.Indeed, have already taken the first .ealthAffairs 1991-10:106-16.mechanlsm.Indeed, we have alreaay taxen tne nrst 3 Bunker J1'.V'ariations in hospital admissions and the appropriateness of care: step in our attempts to set standards or guidelines for American preocctcpations?BMj 1990;301:531-2.the process of medical care.It has even been recognised 4 Enthosen AC.Reflections on the? management ofthe National Health Service: an Amenrcan looks at incentives to efficiencv in health services management in the that standards will have to be regularly reviewed and UK.London: Nuffield Provincial Hospitals Trust, 1985.(Occasional updated on the basis of new knowledge.When this papers 5.)